AUM Biosciences Archives | Be Korea-savvy

Home / Posts tagged AUM Biosciences

AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma

SINGAPORE and BETHESDA, Md., Jan. 5 (Korea Bizwire) — AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) for its product candidate, AUM302, a potential first-in-class oral kinase [...]

AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma

SINGAPORE and BETHESDA, Md., Nov. 30 (Korea Bizwire) — AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation for AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, [...]

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

SINGAPORE and NEW YORK, Oct. 20 (Korea Bizwire) — AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, and Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) (“Mountain Crest”), a publicly-traded special purpose acquisition company formed in Delaware, whose management team [...]

AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2022

SINGAPORE and SEOUL, South Korea, April 19 (Korea Bizwire) – AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing novel targeted oncology therapeutics, Handok Inc. [002390: KOSPI] (“Handok”), a leading innovation-driven pharmaceutical / healthcare company in Korea, and CMG Pharmaceutical Co. Ltd. [058820: KOSDAQ] (“CMG”) today jointly announced Phase 1 data for AUM-601 (CHC2014), a selective second generation [...]